Better Diabetes Diagnoses in Sweden

Area of Science:

• Pediatrics
• Endocrinology
• Immunology

Background:

• The Better Diabetes Diagnosis (BDD) study, a decade-long Swedish initiative, collected data from over 8000 children and adolescents with new-onset diabetes.
• Accurate differentiation between diabetes types in pediatric populations is critical for appropriate management and long-term outcomes.

Purpose of the Study:

• To enhance the diagnostic accuracy for distinguishing type 1 diabetes, type 2 diabetes, and monogenic diabetes (MODY) in children and adolescents.
• To integrate improved diagnostic markers into routine clinical practice for newly diagnosed pediatric diabetes cases.

Main Methods:

• Utilized human leukocyte antigen (HLA) diabetes antibodies and C-peptide level analysis to improve diagnostic discrimination.
• Recommended sequencing of monogenic diabetes (MODY) genes for auto-antibody negative cases with a low type 1 diabetes risk HLA pattern.

Main Results:

• Demonstrated improved discrimination between type 1 and type 2 diabetes through the combined use of HLA antibodies and C-peptide measurements.
• These validated analyses are now standard in the clinical evaluation of all Swedish children and adolescents diagnosed with diabetes.

Conclusions:

• HLA antibodies and C-peptide testing significantly enhance the accuracy of diabetes diagnosis in pediatric patients.
• Early identification of monogenic diabetes (MODY) is essential, warranting genetic sequencing in specific clinical scenarios.
• Despite advancements, a follow-up re-evaluation of the diabetes diagnosis after one year is advisable due to potential initial diagnostic challenges.